NeoGenomics (NASDAQ:NEO – Free Report) had its target price cut by TD Cowen from $22.00 to $19.00 in a research note released on Friday morning, Benzinga reports. They currently have an outperform rating on the medical research company’s stock. A number of other research analysts have also recently commented on NEO. Morgan Stanley upped their […]
FT. MYERS, Fla., January 02, 2024 NeoGenomics will participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco and will present on Monday, Jan. 8, 8:15 p.m. ET.
Needham & Company LLC reiterated their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. The brokerage currently has a $21.00 price target on the medical research company’s stock. Other equities research analysts also recently issued research reports about the company. StockNews.com […]
NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $20.50, but opened at $18.05. NeoGenomics shares last traded at $17.43, with a volume of 713,161 shares traded. Wall Street Analyst Weigh In A number of research analysts have recently weighed in […]
By Ben Glickman Shares of NeoGenomics fell Thursday after the company said it would appeal a preliminary ruling in a patent-infringement lawsuit brought by.